neovascular age-related macular degeneration
Conditions
Interventions
Trade Name: Avastin 25 mg/ml
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Bevacizumab
Concentration unit: mg/ml milligram(s)/millilitre
Concentration number: 25-
Sponsors
Bert Mueller, Dep. Ophthalmology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients older than 50 years, neovascular age related macular degeneration, loss of visual acuity within 3 months prior to inclusion Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: allergy to bevacizumab, contraindication to bevacizumab (unstable Angina pectoris, recent myocardial infarction and stroke), other ocular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): primary endpoint: loss of more than 15 letters ;Main Objective: To test effeciacy and safety of 1mg intravitreal Bevacizumab in patients with neovascular age related macular degeneration and recent loss of visual acuity ;Secondary Objective: to test reading velocity, contrast sensitivity, visual fixation ability, vascular permeability, quality of life questionaire, | — |
Countries
Germany
Outcome results
None listed